

Christoph Zielinski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11658934/publications.pdf>

Version: 2024-02-01

143
papers

9,105
citations

57719

44
h-index

40954

93
g-index

143
all docs

143
docs citations

143
times ranked

12162
citing authors

#	ARTICLE	IF	CITATIONS
1	The cancer survival indexâ€”A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	1.3	7
2	Establishment of aâ€”virtual transborder tumor board for cancer patients in Central and Southeastern Europe. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 697-704.	1.0	2
3	A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Breast Care</i> , 2020, 15, 67-71.	0.8	3
4	Reply to the Correspondence by Untch et al. â€”Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancerâ€”[<i>Breast Care</i> 2019; DOI 10.1159/000500624]. <i>Breast Care</i> , 2020, 15, 314-316.	0.8	0
5	Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. <i>Oncologist</i> , 2020, 25, e598-e601.	1.9	18
6	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. <i>Cells</i> , 2020, 9, 1484.	1.8	7
7	Direct oral anticoagulants compared to lowâ€”molecularâ€”weight heparin for the treatment of cancerâ€”associated thrombosis: Updated systematic review and metaâ€”analysis of randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 550-561.	1.0	69
8	Increased resting heart rate and prognosis in treatmentâ€”naïve unselected cancer patients: results from a prospective observational study. <i>European Journal of Heart Failure</i> , 2020, 22, 1230-1238.	2.9	23
9	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	0.5	34
10	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	0.6	1
11	Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1022-1022.	0.8	2
12	GDFâ€”15 in solid vs nonâ€”solid treatmentâ€”naïve malignancies. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13168.	1.7	10
13	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	0.8	101
14	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. <i>Scientific Reports</i> , 2019, 9, 2554.	1.6	18
15	Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. <i>ESMO Open</i> , 2019, 4, e000550.	2.0	33
16	SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. <i>Translational Oncology</i> , 2019, 12, 15-23.	1.7	8
17	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	0.8	11
18	Characterization of oncologic patient visits at the emergency department (ED) at an Austrian tertiary care center.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6609-6609.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. <i>ESMO Open</i> , 2018, 3, e000262.	2.0	69
20	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1142-1143.	3.0	1
21	Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91.	1.0	102
22	Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group. <i>Oncologist</i> , 2018, 23, e152-e158.	1.9	12
23	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
24	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 508-515.	0.7	2
25	Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. <i>BMC Cancer</i> , 2017, 17, 118.	1.1	27
26	CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology. <i>ESMO Open</i> , 2017, 2, e000194.	2.0	3
27	ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO). <i>ESMO Open</i> , 2017, 2, e000240.	2.0	0
28	Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model. <i>Frontiers in Pharmacology</i> , 2017, 8, 319.	1.6	23
29	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3562-3562.	0.8	1
30	Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutated anaplastic thyroid cancer (ATC). <i>Journal of Clinical Oncology</i> , 2017, 35, 6023-6023.	0.8	16
31	Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study. <i>Journal of Clinical Oncology</i> , 2017, 35, 604-604.	0.8	1
32	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017, 8, 81250-81260.	0.8	15
33	Telemedically Augmented Palliative Care. , 2017, , 1228-1246.		0
34	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. <i>ESMO Open</i> , 2016, 1, e000055.	2.0	28
35	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. <i>ESMO Open</i> , 2016, 1, e000036.	2.0	1
36	Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 109-110.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. <i>Oncologist</i> , 2016, 21, 252-257.	1.9	63
38	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1230-1239.	5.1	55
39	Risk factors for <i>Clostridium difficile</i> infection in hemato-oncological patients: A case control study in 144 patients. <i>Scientific Reports</i> , 2016, 6, 31498.	1.6	26
40	Hypercoagulability, venous thromboembolism, and death in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2016, 115, 817-826.	1.8	58
41	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
42	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 175-180.	0.3	12
43	Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. <i>Journal of Innate Immunity</i> , 2016, 8, 111-120.	1.8	249
44	Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu positive advanced breast cancer: results of the CECOG LaVie trial. <i>BMC Cancer</i> , 2016, 16, 121.	1.1	4
45	Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 163-170.	2.9	19
46	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmmunology</i> , 2016, 5, e1057388.	2.1	239
47	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , 2016, 27, 80-85.	1.1	42
48	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Clinical Cancer Research</i> , 2016, 22, 200-206.	3.2	39
49	Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2072-2072.	0.8	1
50	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8563-8563.	0.8	1
51	Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 234-8.	0.6	8
52	Telemedically Augmented Palliative Care. , 2016, , 183-199.		0
53	Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 582-589.	0.8	187
54	Public Perception of Cancer Care in Poland and Austria. <i>Oncologist</i> , 2015, 20, 28-36.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015, 101, 1874-1880.	1.2	181
56	Influenza vaccination perception and coverage among patients with malignant disease. <i>Vaccine</i> , 2015, 33, 1682-1687.	1.7	47
57	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13026-e13026.	0.8	3
58	Correlation of plasma PD-L1 detectability with age in glioma patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13039-e13039.	0.8	1
59	Nab-paclitaxel as second-line treatment in advanced biliary cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 463-463.	0.8	1
60	Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, e11603-e11603.	0.8	0
61	Individualized treatment schedule and investigator â€™s defined time to resistance (TTRi) may prolong survival in patients with metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2015, 33, e15585-e15585.	0.8	0
62	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13034-e13034.	0.8	0
63	Prognostic impact of breast cancer (BC) subtype in elderly patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20536-e20536.	0.8	0
64	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	1.1	64
65	A Catalyst for Change: The European Cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014, 19, 217-224.	1.9	35
66	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1645-1651.	0.6	63
67	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2014, 111, 670-678.	1.8	88
68	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <i>Thrombosis Research</i> , 2014, 134, 44-49.	0.8	28
69	Amplification and overexpression of <i>CMET</i> is a common event in brain metastases of non-small cell lung cancer. <i>Histopathology</i> , 2014, 65, 684-692.	1.6	25
70	Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort Study. <i>Thrombosis Research</i> , 2014, 134, 1008-1013.	0.8	27
71	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1269-1278.	5.1	118
72	Extracellular Matrix Remodeling by Bone Marrow Fibroblast-like Cells Correlates with Disease Progression in Multiple Myeloma. <i>Journal of Proteome Research</i> , 2014, 13, 844-854.	1.8	46

#	ARTICLE	IF	CITATIONS
73	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	12.5	636
74	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , 2014, 124, 2859-2859.	0.6	3
75	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	0.8	1
76	PD1 and PD-L1 expression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2011-2011.	0.8	4
77	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2012-2012.	0.8	1
78	T-DM1 in HER2-positive breast cancer brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 650-650.	0.8	1
79	The EXACT trial: An individualized treatment protocol for solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14002-e14002.	0.8	1
80	A cross-section study evaluating patients' satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17574-e17574.	0.8	1
81	Public perception of cancer care in Poland and Austria: A survey study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17559-e17559.	0.8	0
82	Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9055-9055.	0.8	1
83	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. <i>Thrombosis Research</i> , 2013, 131, 162-165.	0.8	53
84	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. <i>Lancet Oncology</i> , The, 2013, 14, 125-133.	5.1	107
85	Gliotoxin is a potent <i>NOTCH2</i> transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (<i>CLL</i>) cells. <i>British Journal of Haematology</i> , 2013, 160, 618-629.	1.2	34
86	Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , 2013, 98, 1309-1314.	1.7	65
87	Predictive value of baseline CD66e/CEA serum levels on efficacy of bevacizumab-based treatment in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 388-388.	0.8	0
88	Awareness and understanding of cancer immunotherapy in Europe.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3053-3053.	0.8	0
89	Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3870-3875.	0.8	110
90	High D-dimer levels are associated with poor prognosis in cancer patients. <i>Haematologica</i> , 2012, 97, 1158-1164.	1.7	269

#	ARTICLE	IF	CITATIONS
91	Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review. <i>European Journal of Cancer</i> , 2012, 48, 482-491.	1.3	12
92	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	3.9	163
93	Safety and efficacy of pazopanib in heavily pretreated and treatment-naïve patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15090-e15090.	0.8	1
94	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	0.8	0
95	CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS7113-TPS7113.	0.8	4
96	CD98hc (SLC3A2), a novel biomarker correlating with grade of malignancy in renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15083-e15083.	0.8	0
97	HER3 expression in the primary tumor as marker of metastatic potential in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21033-e21033.	0.8	0
98	Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients â€œ Results From the Vienna Cancer and Thrombosis Study (CATS).. <i>Blood</i> , 2012, 120, 2253-2253.	0.6	0
99	Trastuzumab beyond progression: Overall survival analysis of the GBC 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 2273-2281.	1.3	164
100	The role of fibrinogen plasma levels, the â€œ455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 908-913.	1.8	26
101	Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. <i>Haematologica</i> , 2011, 96, 1008-1014.	1.7	76
102	Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2099-2103.	0.8	196
103	Circulating procoagulant microparticles in cancer patients. <i>Annals of Hematology</i> , 2011, 90, 447-453.	0.8	65
104	Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. <i>BMC Cancer</i> , 2011, 11, 131.	1.1	87
105	Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 64-70.	0.5	236
106	Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis. <i>Blood</i> , 2011, 118, 5124-5124.	0.6	0
107	Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells. <i>Blood</i> , 2011, 118, 4609-4609.	0.6	2
108	Urokinase-Type Plasminogen Activator Receptor (uPAR, CD87) Regulates Integrin Redistribution in Endothelial Cells Via Interaction with Low Density Lipoprotein Receptor- (LDLR-) Like Proteins. <i>Blood</i> , 2011, 118, 5315-5315.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 2513-2521.	0.6	102
110	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , 2010, 116, 5377-5382.	0.6	643
111	Urokinase Receptor (uPAR)-Dependent Integrin Redistribution Represents a Central Mechanism for Growth Factor Induced Endothelial Cell Migration. <i>Blood</i> , 2010, 116, 2119-2119.	0.6	1
112	Disturbance of B-Cell Homeostasis In Chronic Graft-Versus-Host Disease of the Lung. <i>Blood</i> , 2010, 116, 900-900.	0.6	8
113	Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival. <i>Blood</i> , 2010, 116, 2433-2433.	0.6	1
114	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2â€“Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1999-2006.	0.8	685
115	D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4124-4129.	0.8	343
116	Entering a New Era of Rational Biomarker Discovery for Early Detection of Melanoma Metastases: Secretome Analysis of Associated Stroma Cells. <i>Journal of Proteome Research</i> , 2009, 8, 2501-2510.	1.8	51
117	Cytoplasmic Proteome and Secretome Profiles of Differently Stimulated Human Dendritic Cells. <i>Journal of Proteome Research</i> , 2009, 8, 2799-2811.	1.8	48
118	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet</i> , The, 2009, 374, 1432-1440.	6.3	1,062
119	Proportions of immature CD19+CD21â€™ B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2009, 114, 744-746.	0.6	47
120	memo â€“ New official Journal of CECOG. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 2-2.	0.3	0
121	Elevated Numbers of Immature/Transitional CD21â€™ B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 208-219.	2.0	113
122	High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). <i>Blood</i> , 2008, 112, 2703-2708.	0.6	366
123	Carcinoembryonic Antigen (CEA) Regulates Tumor-Angiogenesis in Colon Carcinomas.. <i>Blood</i> , 2008, 112, 1897-1897.	0.6	0
124	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). <i>Blood</i> , 2008, 112, 3824-3824.	0.6	2
125	Venous thromboembolism and survival in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2007, 9, 89-95.	0.6	119
126	Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.. <i>Blood</i> , 2007, 110, 4845-4845.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Expansion of Immature/Transitional B-Lymphocytes in Patients with Active Chronic Graft-Versus-Host Disease.. Blood, 2007, 110, 1065-1065.	0.6	0
128	Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer, 2006, 52, 155-163.	0.9	304
129	Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.. Blood, 2006, 108, 2753-2753.	0.6	5
130	Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.. Blood, 2006, 108, 3398-3398.	0.6	2
131	Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.. Blood, 2006, 108, 2881-2881.	0.6	0
132	Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecologic Oncology, 2005, 97, 514-518.	0.6	19
133	Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer. Molecular Cancer Research, 2005, 3, 335-343.	1.5	133
134	Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial. Journal of Clinical Oncology, 2005, 23, 1401-1408.	0.8	58
135	Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.. Blood, 2005, 106, 4799-4799.	0.6	0
136	Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 2004, 104, 2269-2271.	0.6	156
137	The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.. Blood, 2004, 104, 4873-4873.	0.6	0
138	Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.. Blood, 2004, 104, 3459-3459.	0.6	0
139	Comparative 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1839-1843.	2.2	10
140	Influence of Etoposide on the Retention of Radiolabeled Low-Density Lipoprotein in the Arterial Wall. Archives of Pathology and Laboratory Medicine, 1999, 123, 514-518.	1.2	1
141	BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics. , 1998, 77, 354-360.		81
142	Natural killer cell function in adolescent and adult schizophrenic patients. European Child and Adolescent Psychiatry, 1993, 2, 155-160.	2.8	1
143	Telemedically Augmented Palliative Care. Advances in Healthcare Information Systems and Administration Book Series, 0, , 185-201.	0.2	0